Active Ingredient(s):Eptifibatide FDA Approved: * May 18, 1998 Pharm Company: *SCHERING Category:Intravenous (IV) Therapy
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The ...
* May have multiple approval dates, manufacturers, or labelers. 2 Discussions